CRGX vs. TRVI, CMRX, CRON, QURE, OCS, ANAB, BGM, CRMD, VIR, and KALV
Should you be buying CARGO Therapeutics stock or one of its competitors? The main competitors of CARGO Therapeutics include Trevi Therapeutics (TRVI), Chimerix (CMRX), Cronos Group (CRON), uniQure (QURE), Oculis (OCS), AnaptysBio (ANAB), BGM Group (BGM), CorMedix (CRMD), Vir Biotechnology (VIR), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.
CARGO Therapeutics vs. Its Competitors
Trevi Therapeutics (NASDAQ:TRVI) and CARGO Therapeutics (NASDAQ:CRGX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.
In the previous week, CARGO Therapeutics had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for CARGO Therapeutics and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.04 beat CARGO Therapeutics' score of 0.93 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Trevi Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, CARGO Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 2.9% of CARGO Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Trevi Therapeutics is trading at a lower price-to-earnings ratio than CARGO Therapeutics, indicating that it is currently the more affordable of the two stocks.
CARGO Therapeutics' return on equity of -45.93% beat Trevi Therapeutics' return on equity.
Trevi Therapeutics currently has a consensus target price of $20.88, indicating a potential upside of 165.25%. CARGO Therapeutics has a consensus target price of $15.40, indicating a potential upside of 240.71%. Given CARGO Therapeutics' higher probable upside, analysts plainly believe CARGO Therapeutics is more favorable than Trevi Therapeutics.
Summary
Trevi Therapeutics beats CARGO Therapeutics on 9 of the 14 factors compared between the two stocks.
Get CARGO Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CARGO Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRGX) was last updated on 7/25/2025 by MarketBeat.com Staff
